TY - JOUR
T1 - An acellular pertussis vaccine in healthy adults
T2 - Safety and immunogenicity
AU - Rothstein, Edward P.
AU - Anderson, Edwin L.
AU - Decker, Michael D.
AU - Poland, Gregory A.
AU - Reisinger, Keith S.
AU - Blatter, Mark M.
AU - Jacobson, Robert M.
AU - Mink, Chrisanna M.
AU - Gennevois, Daniel
AU - Izu, Allen E.
AU - Sinangil, F.
AU - Langenberg, Andria G.M.
PY - 1999/8/6
Y1 - 1999/8/6
N2 - Recent data indicate that Bordetella pertussis can be an important cause of illness in adolescents and adults. In a randomized observer- and subject- blinded study, adults (≥18 years of age) received an acellular pertussis (aP) vaccine containing genetically inactivated pertussis toxin (PT), filamentous hemagglutinin (FHA) and pertactin (PRN), or a saline placebo, and were monitored for safety and immunogenicity. IgG antibodies to PT, FHA, and PRN were measured by enzyme-linked immunosorbent assay (ELISA) and PT neutralization by a Chinese hamster ovary (CHO) cell assay. Local reactions, more common in the aP group, were mild and transient. One month after immunization, geometric mean ELISA antibody concentrations for the aP and placebo groups, respectively, were: anti-PT, 463 and 7.6; anti-FHA, 417 and 18; and anti-PRN, 855 and 14. The anti-PT neutralization titers for the aP and placebo groups were 1:3439 and 1:58 respectively. This aP vaccine is a safe and immunogenic candidate booster vaccine against pertussis for adults.
AB - Recent data indicate that Bordetella pertussis can be an important cause of illness in adolescents and adults. In a randomized observer- and subject- blinded study, adults (≥18 years of age) received an acellular pertussis (aP) vaccine containing genetically inactivated pertussis toxin (PT), filamentous hemagglutinin (FHA) and pertactin (PRN), or a saline placebo, and were monitored for safety and immunogenicity. IgG antibodies to PT, FHA, and PRN were measured by enzyme-linked immunosorbent assay (ELISA) and PT neutralization by a Chinese hamster ovary (CHO) cell assay. Local reactions, more common in the aP group, were mild and transient. One month after immunization, geometric mean ELISA antibody concentrations for the aP and placebo groups, respectively, were: anti-PT, 463 and 7.6; anti-FHA, 417 and 18; and anti-PRN, 855 and 14. The anti-PT neutralization titers for the aP and placebo groups were 1:3439 and 1:58 respectively. This aP vaccine is a safe and immunogenic candidate booster vaccine against pertussis for adults.
KW - Acellular pertussis vaccine
KW - Adult immunization
UR - http://www.scopus.com/inward/record.url?scp=0033529606&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=0033529606&partnerID=8YFLogxK
U2 - 10.1016/S0264-410X(99)00164-4
DO - 10.1016/S0264-410X(99)00164-4
M3 - Article
C2 - 10462235
AN - SCOPUS:0033529606
SN - 0264-410X
VL - 17
SP - 2999
EP - 3006
JO - Vaccine
JF - Vaccine
IS - 23-24
ER -